Figure 10.

Uncertainty in projected PASC prevalence when $20\%$ of the population is highly susceptible and experiences $80\%$ of new infections. An estimate of total vaccine efficacy ${\text{VE}}_{\mathrm{T}}$ (2.6) against PASC (a) or secondary efficacy $ϵ$ against PASC conditional on breakthrough infection (b) gives rise to a wide range of possible changes in PASC prevalence, compared with an estimate for primary efficacy $\eta$ against infection (c). Darker shading corresponds to higher primary efficacy ($\eta$). Other parameters as in figure 3.